"Israel Pharmaceuticals & Healthcare Report Q1 2015" now available at Fast Market Research

From: Fast Market Research, Inc.
Published: Fri Feb 06 2015


Israel offers an attractive market to pharmaceutical investors . I ts encouragement of research and development , and gradually improving regulatory regime mean innovative drugmakers will continue to seek opportunities in the country. Meanwhile, despite initiatives to bolster public healthca re funding and improve services, we believe the funding allocation will remain insufficient and that people will continue to look to private healthcare. As a result the market share of private healthcare will continue to grow, entailing more opportunities for companies that can offer services to meet this need.

Headline Expenditure Projections

* Pharmaceuticals: ILS7.31bn (USD2.02bn) in 2013 to ILS7.54bn (USD2.12bn) in 2014; +3.23% in local currency terms and 4.7% in US dollar terms.
* Healthcare: ILS74.01bn (USD20.50bn) in 2013 to ILS78.62bn (USD22.79bn) in 2014; +6.2% in local currency terms and 7.7% in US dollar terms.

Full Report Details at
- http://www.fastmr.com/prod/944729_israel_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=303

Ri sk/Reward Index

The Israeli pharmaceutical sector boasts a number of key qualities. These include a largely urbanised population and a significant pensioner proportion. However, we highlight weak intellectual property (IP) laws and long drug approval times as severe hindrances to multinational drugmakers maximising their returns in the market. In BMI's Pharmaceutical Risk/Reward Index (RRIs) matrix for Q115, the country scores 55.8 out of 100 - unchanged from the previous quarter. This makes it the fifth most attractive market for pharmaceutical investment in the Middle East and Africa (MEA).

Key Trends And Developments

* In December 2014 Teva Pharmaceutical Industries received a positive outcome in the decentralised procedure for its new, three-times weekly Copaxone (glatiramer acetate) 40mg/ml formulation for adults with relapsing forms of multiple sclerosis (RMS). Copaxone is now approved in more than 50 countries worldwide, including the US, Russia, Canada, Mexico, Australia, Israel and all European countries and was Teva's...

The Israel Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Israel Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Israel pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Israel, to test other views - a key input for successful budgeting and strategic business planning in the Israeli pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Egypt Pharmaceuticals & Healthcare Report Q1 2015
- Vietnam Pharmaceuticals & Healthcare Report Q1 2015
- United Arab Emirates Pharmaceuticals & Healthcare Report Q1 2015
- Malaysia Pharmaceuticals & Healthcare Report Q1 2015
- Peru Pharmaceuticals & Healthcare Report Q1 2015
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »